III

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases

Retrieved on: 
Thursday, October 19, 2023

Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI) , a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility.

Key Points: 
  • Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI) , a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility.
  • Dermatological diseases affect more than 900 million people worldwide.
  • Significant advancements in the treatment of various skin conditions and disorders have been made.
  • With the siRNA-based approach, Aldena develops advanced and long-lasting treatments for skin conditions.

ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023

Retrieved on: 
Wednesday, October 18, 2023

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.

Key Points: 
  • ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts highlighting the breadth of its approved and investigational medicines at the 19th Annual European AIDS Conference (EACS 2023) being held in Warsaw, Poland from 18-21 October 2023.
  • Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV Healthcare, said: “Living well with HIV looks different for every individual, and we believe our upcoming presentations at EACS 2023 reflect our commitment and leadership to address the evolving needs of the HIV community.
  • Our latest data from our diverse portfolio and innovative pipeline explore real-world evidence that further evaluate the effectiveness, safety, and tolerability of 2-drug and long-acting regimens; new findings for broadly neutralizing antibodies; and long-term follow-up in heavily treatment-experienced individuals.
  • Here is a list of ViiV Healthcare-sponsored or supported studies being presented at EACS 2023:

Fueling Student Athletes for Peak Performance Takes Precise Nutrition: Aramark Collegiate Hospitality Launches Eat to Excel™ Dining Platform Designed Specifically for Athletes

Retrieved on: 
Wednesday, October 18, 2023

Aramark Collegiate Hospitality (ACH) has launched a performance-based dining platform designed to help student athletes excel on and off the field.

Key Points: 
  • Aramark Collegiate Hospitality (ACH) has launched a performance-based dining platform designed to help student athletes excel on and off the field.
  • View the full release here: https://www.businesswire.com/news/home/20230919458919/en/
    Aramark Collegiate Hospitality (ACH) has launched a performance-based dining platform designed to help student athletes excel on and off the field.
  • Created by Aramark Collegiate Hospitality’s registered dietitians and culinarians, the Eat to Excel™ program features easy-to-understand nutrition education and personalized fueling guidance.
  • Eat to Excel™ was piloted in the spring 2023 semester at select schools and was enthusiastically received by student athletes.

Abiomed to Highlight Data Analysis Identifying Complex Clinical Profile of Patients Receiving Impella-Supported HRPCI at TCT Symposium

Retrieved on: 
Monday, October 23, 2023

The seven studies include an analysis of the characteristics of PROTECT III patients that demonstrates how physicians are distinguishing which patients are high-risk and appropriate for Impella-supported HRPCI procedures.

Key Points: 
  • The seven studies include an analysis of the characteristics of PROTECT III patients that demonstrates how physicians are distinguishing which patients are high-risk and appropriate for Impella-supported HRPCI procedures.
  • The data shows that 82.5 percent of patients have features in all three high-risk domains: comorbidities, complex coronary anatomy and adverse hemodynamics.
  • It also demonstrates that 99.6 percent of patients have risk factors from two or more of the high-risk domains.
  • Abiomed's World Connect TCT Symposium takes place on Tuesday, Oct. 24 between 11 a.m.–12 p.m. PDT on Level 2 in the Presentation Theater.

InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea

Retrieved on: 
Friday, October 20, 2023

The information was submitted for publication through the agency of the contact person set out above at 14:10 CET on October 20, 2023.

Key Points: 
  • The information was submitted for publication through the agency of the contact person set out above at 14:10 CET on October 20, 2023.
  • InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.
  • InDex has also developed patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
  • The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

InDex Pharmaceuticals has been granted a new patent for cobitolimod in South Korea

Retrieved on: 
Friday, October 20, 2023

The information was submitted for publication through the agency of the contact person set out above at 14:10 CET on October 20, 2023.

Key Points: 
  • The information was submitted for publication through the agency of the contact person set out above at 14:10 CET on October 20, 2023.
  • InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options.
  • InDex has also developed patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
  • The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.

Immuno-Oncology360º Announces 2024 Keynotes and Featured Speakers for the 10th Annual NYC Meeting

Retrieved on: 
Thursday, October 19, 2023

NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.

Key Points: 
  • The Conference Forum announced the IO360º Summit's 2024 keynotes and featured speakers for its 10th annual conference.
  • NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.
  • The IO360° 2024 keynotes include:
    Genentech's Ira Mellman, PhD, VP, Cancer Immunology, will speak on the roles of data mining and AI, and other clinical and translational data, in discovery and trial design.
  • "The IO360º conference presents the latest data impacting the IO landscape and for the 10th annual event, we are pleased to announce the extraordinary leadership advancing this space.

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

Retrieved on: 
Thursday, October 19, 2023

A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.

Key Points: 
  • A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.
  • The study was submitted under the new Clinical Trial Regulation, and it is expected to start the activation process in the fourth quarter of 2023.
  • "We are excited to offer to our high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer patients the possibility to participate in the Treat ctDNA trial.
  • This intergroup trial, managed by the EORTC Breast Cancer Group, will be jointly conducted with several national and international cancer clinical research groups, including the German SUCCESS group under the umbrella of BIG (Breast International Group).

Earl B. Parsons, III Named General Counsel at UtilityInnovation Group

Retrieved on: 
Thursday, October 19, 2023

RALEIGH, N.C., Oct. 19, 2023 /PRNewswire/ -- Earl B. Parsons, III, former Deputy General Counsel – Commercial with Southern Company, and most recently a partner at Atlanta's Taylor English Duma LLP's law firm, has been named General Counsel at UtilityInnovation Group (UIG).

Key Points: 
  • RALEIGH, N.C., Oct. 19, 2023 /PRNewswire/ -- Earl B. Parsons, III, former Deputy General Counsel – Commercial with Southern Company, and most recently a partner at Atlanta's Taylor English Duma LLP's law firm, has been named General Counsel at UtilityInnovation Group (UIG).
  • His unique experience equips him to accelerate UIG's growth."
  • "We are thrilled to have Earl join our leadership team."
  • Additionally, Parsons provided legal oversight of contracting and transactional activities for Southern Company and its subsidiaries, surpassing $5 billon USD annually.

EQS-News: Kontron AG: Convocation of Extraordinary General Meeting

Retrieved on: 
Wednesday, October 18, 2023

Only persons who are shareholders on the record date and can prove this to the Company shall be entitled to attend the General Meeting.

Key Points: 
  • Only persons who are shareholders on the record date and can prove this to the Company shall be entitled to attend the General Meeting.
  • Insofar as Kontron AG uses external service providers to organise the General Meeting (e.g.
  • Any change in the number of treasury shares before the General Meeting and thereby in the total number of voting rights will be announced at the General Meeting.
  • This Extraordinary General Meeting is expected to have a short duration and so we ask for your understanding that the only refreshments provided will be in the form of drinks.